6.52
0.04 (0.62%)
| Previous Close | 6.48 |
| Open | 6.50 |
| Volume | 595,283 |
| Avg. Volume (3M) | 1,102,570 |
| Market Cap | 408,286,976 |
| Price / Sales | 11.72 |
| Price / Book | 1.39 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -476.01% |
| Diluted EPS (TTM) | -5.80 |
| Quarterly Revenue Growth (YOY) | 78.00% |
| Total Debt/Equity (MRQ) | 2.89% |
| Current Ratio (MRQ) | 9.13 |
| Operating Cash Flow (TTM) | -311.09 M |
| Levered Free Cash Flow (TTM) | -179.04 M |
| Return on Assets (TTM) | -36.35% |
| Return on Equity (TTM) | -63.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sage Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.41% |
| % Held by Institutions | 83.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (HC Wainwright & Co., 84.05%) | Hold |
| Median | 9.00 (38.04%) | |
| Low | 8.50 (Canaccord Genuity, 30.37%) | Hold |
| 8.50 (Piper Sandler, 30.37%) | Hold | |
| Average | 9.37 (43.71%) | |
| Total | 6 Hold | |
| Avg. Price @ Call | 9.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 08 Jul 2025 | 9.20 (41.10%) | Hold | 9.12 |
| Baird | 20 Jun 2025 | 9.00 (38.04%) | Hold | 9.30 |
| Canaccord Genuity | 17 Jun 2025 | 8.50 (30.37%) | Hold | 9.12 |
| HC Wainwright & Co. | 17 Jun 2025 | 12.00 (84.05%) | Hold | 9.12 |
| Piper Sandler | 17 Jun 2025 | 8.50 (30.37%) | Hold | 9.12 |
| Truist Securities | 17 Jun 2025 | 9.00 (38.04%) | Hold | 9.12 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary |
| 16 Jun 2025 | Announcement | Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio |
| 29 Apr 2025 | Announcement | Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates |
| 15 Apr 2025 | Announcement | Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |